안정화된 만성 정신분열병 환자에서 주관적 삶의 질에 미치는 Haloperidol과 Risperidone의 영향

다국어 초록 (Multilingual Abstract)

Objective：The purpose of this study is to compare the effects of haloperidol and risperidone on the
quality of life in chronic schizophrenic patients and to identify how the quality of life is related with the
severity of psychopathology and drug side effects.
Methods：The study sample was composed of 38 ambulatory patients on haloperidol 1.5-4.5mg/day
and 33 patients on risperidone 1-4mg/day for more than 2 years. They were physically healthy and had
diagnoses of chronic undifferentiated or residual type of schizophrenia according to the criteria of DSM-
Ⅳ. Those who had other comorbid mental disorders were excluded. For the assessment of the quality of
life(QOL), the Korean version of WHOQOL was used. The severity of psychotic symptoms was evaluated
by BPRS, and the side effects of the medication was evaluated by UKU Side Effects Rating Scales.
Results：The results showed that sex, age, education level, marital states, duration of antipsychotic
medication and BPRS scores were not significantly different between the haloperidol group and risperidone
group. But, the UKU Side Effects Rating Scales scores in the haloperidol group were significantly higher
than those in the risperidone group. The mean score of the WHOQOL-BREF in the risperidone group
was a little higher than that in the haloperidol group, and in the same way the 3 domain scores of the
WHOQOL-BREF(physical, psychological, environmental domains) in the risperidone group was a little
higher than those in the haloperidol group. However, the differences were not statistically significant
between the two groups. There was a negative correlation between total QOL score and total BPRS scores,
and both between BPRS item of tension and the total QOL score and between depressive mood and total
QOL score. But, there was no correlation between total QOL score and UKU side effect scores.
Conclusions：This study suggests that, if schizophrenia has once become chronic, the quality of life
is not significantly influenced by the kind of antipsychotic drugs in the maintenance dose, and that the
quality of life is correlated with a severity of the symptoms, especially tension and depressive mood.